Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. Mai 2018 08:00 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting

NEW HAVEN, Conn., May 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
07. Mai 2018 07:00 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria

NEW HAVEN, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
27. April 2018 16:15 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018

NEW HAVEN, Conn., April 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
23. April 2018 08:00 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations

NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
23. April 2018 07:30 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018

NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
16. April 2018 08:00 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018

NEW HAVEN, Conn., April 16, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
14. März 2018 08:00 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference

NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
13. März 2018 16:35 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather

NEW HAVEN, Conn., March 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
13. März 2018 07:00 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Baxdela™(delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI Acquired Infectious Disease Business from The Medicines Company on January 5, 2018 First Earnings Report as a Public...
08. März 2018 07:00 ET | Quelle: Melinta Therapeutics

Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe

NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...

Vorherige Seite

Nächste Seite